Cargando…

The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis

BACKGROUND: Multi-matrix mesalazine (MMX) is an important treatment for ulcerative colitis (UC); however, it is often excreted intact, which increases the risk of relapse. This study aimed to clarify the risk factors for insoluble MMX excretion. METHODS: The subjects were 102 UC patients who were ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuichiro, Ohtaki, Kan, Uchiyama, Hirotaka, Kamiya, Eri, Moriizumi, Moe, Yamada, Yuma, Aoki, Toshimune, Watanabe, Sachie, Kiryu, Sizuka, Suzuki, Yoshihiro, Matsumoto, Zensho, Ito, Toshifumi, Ohkusa, Shigeo, Koido, Masayuki, Saruta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389853/
https://www.ncbi.nlm.nih.gov/pubmed/35982420
http://dx.doi.org/10.1186/s12876-022-02474-9
_version_ 1784770545927061504
author Yuichiro, Ohtaki
Kan, Uchiyama
Hirotaka, Kamiya
Eri, Moriizumi
Moe, Yamada
Yuma, Aoki
Toshimune, Watanabe
Sachie, Kiryu
Sizuka, Suzuki
Yoshihiro, Matsumoto
Zensho, Ito
Toshifumi, Ohkusa
Shigeo, Koido
Masayuki, Saruta
author_facet Yuichiro, Ohtaki
Kan, Uchiyama
Hirotaka, Kamiya
Eri, Moriizumi
Moe, Yamada
Yuma, Aoki
Toshimune, Watanabe
Sachie, Kiryu
Sizuka, Suzuki
Yoshihiro, Matsumoto
Zensho, Ito
Toshifumi, Ohkusa
Shigeo, Koido
Masayuki, Saruta
author_sort Yuichiro, Ohtaki
collection PubMed
description BACKGROUND: Multi-matrix mesalazine (MMX) is an important treatment for ulcerative colitis (UC); however, it is often excreted intact, which increases the risk of relapse. This study aimed to clarify the risk factors for insoluble MMX excretion. METHODS: The subjects were 102 UC patients who were newly prescribed MMX alone to induce remission. Their stools were evaluated on the Bristol Stool Form Scale (BSFS), the presence/absence of insoluble MMX excretion was investigated in interviews, and defecation frequency at the start of treatment and disease type were retrospectively investigated by examining their medical records. RESULTS: The insoluble excretion rate (IER) was 14.7%. It tended to be higher in the patients with left-sided colitis or extensive colitis, although the differences among the disease types were not significant (p = 0.053). The mean defecation frequency of the patients that reported insoluble MMX excretion was significantly higher than that of the patients that did not report it (6.27 ± 5.28 vs. 3.69 ± 3.17, p < 0.05). The IER tended to be higher among the patients with soft stools (4.5%, 21.9%, and 23.1% in those with BSFS scores of ≤ 4, 5, and ≥ 6, respectively). In ROC analysis of defecation frequency, ≥ 3.5 defecations was found to exhibit sensitivity and specificity of 66.7% and 65.5%, respectively, for predicting insoluble MMX excretion. CONCLUSIONS: The likelihood of insoluble MMX excretion is influenced by defecation frequency and the extent of inflammation. It is important to keep the possibility of insoluble excretion in mind when prescribing MMX.
format Online
Article
Text
id pubmed-9389853
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93898532022-08-20 The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis Yuichiro, Ohtaki Kan, Uchiyama Hirotaka, Kamiya Eri, Moriizumi Moe, Yamada Yuma, Aoki Toshimune, Watanabe Sachie, Kiryu Sizuka, Suzuki Yoshihiro, Matsumoto Zensho, Ito Toshifumi, Ohkusa Shigeo, Koido Masayuki, Saruta BMC Gastroenterol Research BACKGROUND: Multi-matrix mesalazine (MMX) is an important treatment for ulcerative colitis (UC); however, it is often excreted intact, which increases the risk of relapse. This study aimed to clarify the risk factors for insoluble MMX excretion. METHODS: The subjects were 102 UC patients who were newly prescribed MMX alone to induce remission. Their stools were evaluated on the Bristol Stool Form Scale (BSFS), the presence/absence of insoluble MMX excretion was investigated in interviews, and defecation frequency at the start of treatment and disease type were retrospectively investigated by examining their medical records. RESULTS: The insoluble excretion rate (IER) was 14.7%. It tended to be higher in the patients with left-sided colitis or extensive colitis, although the differences among the disease types were not significant (p = 0.053). The mean defecation frequency of the patients that reported insoluble MMX excretion was significantly higher than that of the patients that did not report it (6.27 ± 5.28 vs. 3.69 ± 3.17, p < 0.05). The IER tended to be higher among the patients with soft stools (4.5%, 21.9%, and 23.1% in those with BSFS scores of ≤ 4, 5, and ≥ 6, respectively). In ROC analysis of defecation frequency, ≥ 3.5 defecations was found to exhibit sensitivity and specificity of 66.7% and 65.5%, respectively, for predicting insoluble MMX excretion. CONCLUSIONS: The likelihood of insoluble MMX excretion is influenced by defecation frequency and the extent of inflammation. It is important to keep the possibility of insoluble excretion in mind when prescribing MMX. BioMed Central 2022-08-18 /pmc/articles/PMC9389853/ /pubmed/35982420 http://dx.doi.org/10.1186/s12876-022-02474-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yuichiro, Ohtaki
Kan, Uchiyama
Hirotaka, Kamiya
Eri, Moriizumi
Moe, Yamada
Yuma, Aoki
Toshimune, Watanabe
Sachie, Kiryu
Sizuka, Suzuki
Yoshihiro, Matsumoto
Zensho, Ito
Toshifumi, Ohkusa
Shigeo, Koido
Masayuki, Saruta
The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
title The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
title_full The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
title_fullStr The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
title_full_unstemmed The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
title_short The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
title_sort insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389853/
https://www.ncbi.nlm.nih.gov/pubmed/35982420
http://dx.doi.org/10.1186/s12876-022-02474-9
work_keys_str_mv AT yuichiroohtaki theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT kanuchiyama theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT hirotakakamiya theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT erimoriizumi theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT moeyamada theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT yumaaoki theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT toshimunewatanabe theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT sachiekiryu theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT sizukasuzuki theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT yoshihiromatsumoto theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT zenshoito theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT toshifumiohkusa theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT shigeokoido theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT masayukisaruta theinsolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT yuichiroohtaki insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT kanuchiyama insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT hirotakakamiya insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT erimoriizumi insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT moeyamada insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT yumaaoki insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT toshimunewatanabe insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT sachiekiryu insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT sizukasuzuki insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT yoshihiromatsumoto insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT zenshoito insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT toshifumiohkusa insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT shigeokoido insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis
AT masayukisaruta insolubleexcretionofmultimatrixsystemmesalazinepreparationsinpatientswithulcerativecolitis